UBS lowered the firm’s price target on CureVac to $14 from $18 and keeps a Buy rating on the shares. The firm thinks oncology and IP updates this year could drive upside for shares, the analyst tells investors in a research note. UBS continues to see value in CureVac’s mRNA platform long-term and thinks the data to date from the COVID and flu vaccines is supportive of CureVac’s platform, though it believes the platform is undervalued relative to the broader mRNA space.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- Curevac’s Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
- CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
- CureVac Launches Study for H5N1 Influenza Vaccine
- CureVac Names New Chief Business Officer
- CureVac, GSK terminate Pandemic Preparedness Agreement